ArticleEuropean journal of hospital pharmacy : science and practice2023
Managing the risk of shortages and medication errors with curares during the COVID-19 pandemic: a hospital pharmacy experience.
Article in European journal of hospital pharmacy : science and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- An analysis of cases referred to Polish prosecutor's offices involving suspected medical errors directly and indirectly connected with the COVID-19 pandemic.Anaesthesiology intensive therapy · 2025Article
- A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging.Therapeutic advances in drug safety · 2025Review
- Addressing Drug Shortages at Mediclinic Parkview Hospital: A Five-Year Study of Challenges, Impact, and Strategies.Cureus · 2024Article
- Post-pandemic patient safety: have the characteristics of incidents with harm changed? Comparative observational study in primary care via review of medical records with a trigger tool.BMC primary care · 2024Observational
- Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience.Frontiers in public health · 2023Article
- An Assessment of Outpatient Satisfaction with Hospital Pharmacy Quality and Influential Factors in the Context of the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2022Article
- Using fungible biosensors to evolve improved alkaloid biosyntheses.Nature chemical biology · 2022Article
- Biosynthesis of tetrahydropapaverine and semisynthesis of papaverine in yeast.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia.Research in social & administrative pharmacy : RSAP · 2022Review
- Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units.Journal of pharmaceutical policy and practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) has spread rapidly around the world. Like many clinical teams, hospital pharmacies have widely contributed in preventing and containing the COVID-19 pandemic. Pharmacies were thus involved in the management of overuse of specific drugs, medication shortages and risk of medication errors.
objectivesTo assess the use of curares during the COVID-19 crisis and to highlight the lessons to be learnt from this overuse.
methodsThe use of curares (Atracurium, Cisatracurium and Rocuronium) was compared with the usual use levels in our hospital. Supply issues have been identified and investigated. The risk of medication errors was clearly established and considered.
resultsDespite an increased demand, our hospital has not experienced any disruption in the supply of curare medications. But the risk of curare shortages has led to the registration of new pharmaceutical forms and dosages never used before. We also observed necessary switches between different curares. All of this has contributed to an increased risk of medication errors.
conclusionsDuring the COVID-19 pandemic, the pharmaceutical management of curare medications has been particularly critical. The risk of medication errors and unsafe medication practices was high. This analysis must lead to a high level of vigilance in the next few months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.